公开(公告)号：US10857131B2

公开(公告)日：2020-12-08

申请号：US15611614

申请日：2017-06-01

Applicant: Celgene International II Sàrl

Inventor： Mohit Trikha ,  Ann MacLaren ,  Nancy Levin

IPC: A61K31/495 ,  A61K31/407 ,  A61K39/395 ,  C07K16/22 ,  C07K16/28 ,  A61N5/10 ,  A61K39/00

Abstract: The present disclosure relates to treatment of central nervous system (CNS) cancers (e.g., malignant glioma, glioblastoma, or CNS-multiple myeloma) using marizomib. The disclosure further relates to uses of synergistic combinations of marizomib with additional therapeutic agents such as bevacizumab, daratumumab, temozolomide, pomalidomide, and radiotherapy.

公开(公告)号：US20210169851A1

公开(公告)日：2021-06-10

申请号：US17094495

申请日：2020-11-10

Applicant: Celgene International II Sàrl

Inventor： Mohit Trikha ,  Nancy Levin ,  Ann MacLaren

IPC: A61K31/407 ,  A61K39/395 ,  A61K31/495 ,  A61N5/10 ,  C07K16/22 ,  C07K16/28

Abstract: The present disclosure relates to treatment of central nervous system (CNS) cancers (e.g., malignant glioma, glioblastoma, or CNS-multiple myeloma) using marizomib. The disclosure further relates to uses of synergistic combinations of marizomib with additional therapeutic agents such as bevacizumab, daratumumab, temozolomide, pomalidomide, and radiotherapy.

公开(公告)号：US10894036B2

公开(公告)日：2021-01-19

申请号：US15611614

申请日：2017-06-01

Applicant: Celgene International II Sàrl

Inventor： Mohit Trikha ,  Ann MacLaren ,  Nancy Levin

IPC: A61K31/495 ,  A61K31/407 ,  A61K39/395 ,  C07K16/22 ,  C07K16/28 ,  A61N5/10 ,  A61K39/00

Abstract: The present disclosure relates to treatment of central nervous system (CNS) cancers (e.g., malignant glioma, glioblastoma, or CNS-multiple myeloma) using marizomib. The disclosure further relates to uses of synergistic combinations of marizomib with additional therapeutic agents such as bevacizumab, daratumumab, temozolomide, pomalidomide, and radiotherapy.